Drug Trial Radar · NCT02864004
Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Mar 3, 2017
Primary completion
Jan 12, 2024
Study completion Jan 10, 2025
Sponsor
- Lead sponsor
- Rennes University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the use of the apomorphine pump in earlier stages of Parkinson' Disease (PD), when motor complications have just developed and before patients are significantly affected in their social and occupational functioning. The investigators hypothesize that apomorphine pump is superior in terms of positive impact on quality of life (QoL) to oral medical therapy alone at a relatively early stage of PD, before the appearance of severe disabling motor complications thus favoring the maintain of patients' social and occupational status with a significant positive economic impact of the health system.
Conditions
- Parkinson's Disease
Interventions
ApomorphineDrug
Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
Best Medical TreatmentOther
Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference in the Parkinson's Disease Quality of Life Questionnaire (PDQ39) summary index between the baseline assessment and the assessment at 12 months' follow upTime frame: 12 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Amiens University Hospital
Amiens, France
Bayonne Côte Basque Hospital
Bayonne, France
Pellegrin University Hospital
Bordeaux, France
Pierre Wertheimer Hospital
Bron, France
Caen University Hospital
Caen, France
Clermont-Ferrand University Hospital
Clermont-Ferrand, France
Lille University Hospital
Lille, France
APHM, hospital of Timone
Marseille, France
Clinique Beau-Soleil
Montpellier, France
Montpellier University Hospital
Montpellier, France
Nancy University Hospital
Nancy, France
Laennec Hospital
Nantes, France
Pasteur 2 University Hospital
Nice, France
Caremeau University Hospital
Nîmes, France
Pitié-Salpêtriere Hospital
Paris, France
Poitiers University Hospital
Poitiers, France
Rennes University Hospital
Rennes, France
Saint-Etienne University Hospital
Saint-Etienne, France
Hautepierre University Hospital
Strasbourg, France
Purpan University Hospital
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.